Epidemiology of schizophrenic disorders;Épidémiologie des troubles schizophréniques

Presse Medicale

Volumn 35, Issue 3 II, 2006, Pages 461-468

  Hautecouverture, Stéphane ^a   Limosin, Frédéric ^b   Rouillon, Frédéric ^c  

^a Hopital Albert Chenevier   (France)

^b SERVICE DE DERMATOLOGIE   (France)

^c CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT;

AGE DISTRIBUTION; DEMOGRAPHY; ENVIRONMENTAL FACTOR; FRANCE; GROUPS BY AGE; HEREDITY; HUMAN; LIFE EXPECTANCY; MARRIAGE; MORTALITY; NERVE CELL DIFFERENTIATION; OUTCOME ASSESSMENT; RELATIVE; REVIEW; SCHIZOPHRENIA; SEX RATIO; ADOLESCENT; ADULT; ARTICLE; ENVIRONMENT; FEMALE; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTOR; SOCIOECONOMICS;

ADOLESCENT; ADULT; ENVIRONMENT; FEMALE; HUMANS; INCIDENCE; MALE; MARITAL STATUS; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTORS; SCHIZOPHRENIA; SOCIOECONOMIC FACTORS;

EID: 33645280892     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74620-6     Document Type: Article

References (43)

1. Andreasen N. Diagnostic, évaluation et substratum neuropathologique de la schizophrénie. Schizophrénie. Paris, Laboratoires Sandoz Triangle Ed: 1994; 34: 5-9.
2. Crow TJ. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry. 1980; 137: 383-6.
3. e edition, 1990.
4. Organisation Mondiale de la Santé. Classification internationale des troubles mentaux et des troubles du comportement. Paris: Masson; 1993.
5. NIMH Diagnostic Interview Schedule, version III Revised. St Louis, Mo: Washington University; 1989.
6. Composite International Diagnostic Interview, version 2.1, 1998, Genève, Organisation Mondiale de la Santé, division de la santé mentale.
7. Keith SJ, Regier DA, Rae DS. Schizophrénic disorders. Robins LN, Regnier DA, editors, Psychiatric Disorders in America. The Epidemiologic Catchment Area Study. New York: The Free Press, 1991, p. 33-52.
8. Jablenski A. Epidemiology of schizophrenia: a European perspective. Schizophr Bull. 1986; 12: 52-73.
9. Sartorius N, Jablensky A, Korten A, Ernberg G, Anker M, Cooper JE et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med. 1986; 16 (4): 909-28.
10. Munk-Jorgensen P, Mortensen PB. Is schizophrenia really on the decrease? Eur Arch Psychiatry Clin Neurosci. 1993; 242 (4): 244-7.
11. Parker G, O'Donnell M, Walter S. Changes in the diagnoses of the functional psychoses associated with the introduction of lithium. Br J Psychiatry. 1985; 146: 377-82.
12. Bourgeois M, Etchepare JJ, Degeilh B, Rager P, Peyre F. L'évolution des schizophrénies. Problèmes méthodologiques et revue de la littérature. Ann Med Psychol.1987; 145 (7): 608-20.
13. Lee PW, Lieh-Mak F, Yu KK, Spinks JA. Patterns of outcome in schizophrenia in Hong Kong. Acta Psychiatr Scand. 1991; 84 (4): 346-52.
14. Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry. 1993; 54 Suppl: 13-7.
15. Marneros A. Évolution à long terme et pronostic de la schizophrénie. In: Schizophrénie. Paris: Laboratoires Sandoz, Triangles Ed; 1994, 34: 35-42.
16. Rouillon F, Dansette GY, Le Floch C. Therapeutic management of schizophrenic patients and its cost. Encephale. 1994; 20 (3): 303-9.
17. Childers SE, Harding CM. Gender, premorbid social functioning, and long-term outcome in DSM-III schizophrenia. Schizophr Bull. 1990; 16 (2): 309-18.
18. Ciompi L. Influence du vieillissement sur la schizophrénie. In: Schizophrénie. Laboratoires Sandoz, Triangle Ed; 1994, 34: 35-54.
19. Ciompi L. Learning from outcome studies. Toward a comprehensive biological-psychosocial understanding of schizophrenia. Schizophr Res. 1988 Nov-Dec; 1 (6): 373-84.
20. Cohen CI, Sokolovsky J. Schizophrenia and social networks: ex-patients in the inner city. Schizophr Bull. 1978; 4 (4): 546-60.
21. Wyatt RJ, Fawcett R, Kirch D. A possible animal model of defect state schizophrenia. Schulz SC, Tammingra CA, editors. Schizophrenia. New York: Scientific Progress, Oxford University Press. 1989: p. 184-9.
22. Iacono WG, Beisser M. Age of onset and temporal stability in the eighteen month course of first episode psychosis. In: Cichetti D, ed. Developmental Psychopathology.
23. Casadebaig F, Quemada N, Chevalier A. Évolution de la mortalité des malades mentaux hospitalisés, 1968-1982. Rev Epidemiol Sante Publigue. 1990; 38 (3): 227-36.
24. Tsuang MT, Woolson RF. Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess? Arch Gen Psychiatry 1978; 35 (10): 1181-5.
25. Tabbane K, Joober R, Spadone C, Poirier MF, Olie JP. Mortalité et causes de décès dans la schizophrénie. Encephale. 1993; 19 (1): 23-8.
26. Cardno AG, Gottesman II. Twin studies of schizophrenia. Am J Med Genet Semin Med Genet. 2000; 97: 12-7.
27. Gottesman II, Shields J. Schizophrenia, the epigenetic puzzle. Cambridge: Cambridge University Press, 1982.
28. Limosin F, Rouillon F, Payan C, Cohen JM, Strub N. Prenatal exposure to influenza as a risk factor for adult schizophrenia. Acta Psychiatr Scand. 2003; 107: 331-5.
29. Brown A, Begg M, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004; 61: 774-80.
30. Crow TJ. Prenatal exposure to influenza as a cause of schizophrenia. There are inconsistencies and contradictions in the evidence. Br J Psychiatry. 1994; 164 (5): 588-92.
31. Lewis SW. Congenital risk factors for schizophrenia. Psychol Med. 1998; 19: 5-13.
32. O'Callaghan E, Larkin C, Waddington JL. Obstetric complications in schizophrenia and the validity of maternal recall. Psychol Med. 1990; 20 (1): 89-94.
33. Jones P, Cannon M. The new epidemiology of schizophrenia. Psychiatr Clin North Am. 1998; 21 (1): 1-25.
34. Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. Int J Epidemiol. 1997; 26 (4): 837-43.
35. Birley JL, Brown GW. Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. Br J Psychiatry. 1970; 116 (532): 327-33.
36. Harrison G, Glazebrook C, Brewin J, Cantwell R, Dalkin T, Fox R et al. Increased incidence of psychotic disorders in migrants from the Caribbean to the United Kingdom. Psychol Med. 1997; 27 (4): 799-806.
37. Potvin S, Stip E, Roy JY. Schizophrénie et toxicomanie: une relecture du concept d'automédication. Encephale. 2003; 29 (3 Pt 1): 193-203.
38. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264 (19): 2511-8.
39. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffit TE. Cannabis use in adolescence and risgue for adult psychosis: longitudinal prospective study. Br Med J. 2002; 325: 1212-3.
40. Patton GC, Coffey C, Carlin JB, Degenhard L, Lynskey M, Hall W. Cannabis use and mental health in young people: cohort study. Br Med J. 2002; 325: 1195-8.
41. Os J, Bak M, Hanssen M, Biji RV, Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol. 2002; 156 (4): 319-26.
42. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969:historical cohort study. Br Med J. 2002; 325: 1199-201.
43. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry. 2004; 184: 110-7.